Biological E. COVID shot gets India emergency approval for 12-18 age group

March 2, 2022 Gubba Pharma In E News

Indian vaccine maker Biological E . Ltd said its COVID-19 vaccine received an emergency use approval in the country for use in children aged 12 to 18. The company’s shot, called Corbevax, is the third vaccine approved for use in children aged 12 and above in India, joining Zydus Cadila ‘s DNA shot ZyCoV-D and homegrown player Bharat Biotech’s Covaxin.
India has so far only started vaccinating children aged 15 and above. According to government figures, more than 76 million children between 15 and 17 have been inoculated mainly using Covaxin. The emergency use approval for restricted use in the 12-18 age group for Corbevax is based on interim results of an ongoing mid- to late-stage clinical study, Biological E. said in an emailed statement. Nearly 1.76 billion vaccine doses have been used in India’s vaccination programme so far, of which about 84% has been a domestic version of AstraZeneca’s COVID-19 shot produced by the Serum Institute of India. India’s third wave of COVID-19 cases driven by the Omicron coronavirus variant has largely receded, with the country reporting 16,051 infections compared to more than 300,000.

Source: EconomicTimes

Gubba Group

About the author

Gubba Group: